ethyl 2-(1-(4-fluorobenzyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)-4-methylthiazole-5-carboxylate | 1072804-06-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 2-(1-(4-fluorobenzyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)-4-methylthiazole-5-carboxylate
• 英文别名: ethyl 2-[1-[(4-fluorophenyl)methyl]-5-oxo-1,2,4-triazol-4-yl]-4-methyl-1,3-thiazole-5-carboxylate
• CAS: 1072804-06-8
• 化学式: C₁₆H₁₅FN₄O₃S
• 分子量: 362.385
• InChiKey: ZEOQOQQZCBHKJG-UHFFFAOYSA-N

物化性质

• 沸点：
  486.3±55.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  103
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  ethyl 2-(1-(4-fluorobenzyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)-4-methylthiazole-5-carboxylate 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 以73%的产率得到2-(1-(4-fluorobenzyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)-4-methylthiazole-5-carboxylic acid
  参考文献：
  名称：

  Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors

  摘要：

  Stearoyl-CoA desaturase-1 (SCD1) plays an important role in lipid metabolism. Inhibition of SCD1 activity represents a potential novel approach for the treatment of metabolic diseases such as obesity, type 2 diabetes and dyslipidemia, as well as skin diseases, acne and cancer. Herein, we report the synthesis and structure-activity relationships (SAR) of a series of novel triazolone derivatives, culminating in the identification of pyrazolyltriazolone 17a, a potent SCD1 inhibitor, which reduced plasma C16:1/C16:0 triglycerides desaturation index (DI) in an acute Lewis rat model in a dose dependent manner, with an ED50 of 4.6 mg/kg. In preliminary safety studies, compound 17a did not demonstrate adverse effects related to SCD1 inhibition after repeat dosing at 100 mg/kg. Together, these data suggest that sufficient safety margins can be achieved with certain SCD1 inhibitors, thus allowing exploration of clinical utility in metabolic disease settings. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.12.014
• 作为产物：
  描述：

  2-氨基-4-甲基噻唑-5-甲酸乙酯 在 吡啶 、 potassium carbonate 、 对甲苯磺酸 、 一水合肼 作用下， 以 四氢呋喃 、 乙醇 、 丙酮 为溶剂， 反应 12.17h， 生成 ethyl 2-(1-(4-fluorobenzyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)-4-methylthiazole-5-carboxylate
  参考文献：
  名称：

  Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors

  摘要：

  Stearoyl-CoA desaturase-1 (SCD1) plays an important role in lipid metabolism. Inhibition of SCD1 activity represents a potential novel approach for the treatment of metabolic diseases such as obesity, type 2 diabetes and dyslipidemia, as well as skin diseases, acne and cancer. Herein, we report the synthesis and structure-activity relationships (SAR) of a series of novel triazolone derivatives, culminating in the identification of pyrazolyltriazolone 17a, a potent SCD1 inhibitor, which reduced plasma C16:1/C16:0 triglycerides desaturation index (DI) in an acute Lewis rat model in a dose dependent manner, with an ED50 of 4.6 mg/kg. In preliminary safety studies, compound 17a did not demonstrate adverse effects related to SCD1 inhibition after repeat dosing at 100 mg/kg. Together, these data suggest that sufficient safety margins can be achieved with certain SCD1 inhibitors, thus allowing exploration of clinical utility in metabolic disease settings. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.12.014

文献信息

• [EN] HETEROCYCLIC INHIBITORS OF STEAROYL-COA DESATURASE<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE LA STÉAROYL-COA DÉSATURASE
  申请人：NOVARTIS AG

  公开号：WO2009103739A1

  公开（公告）日：2009-08-27

  The present invention provides heterocyclic derivatives of formula (I) that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了式（I）的杂环衍生物，可调节硬脂酰辅酶A去饱和酶的活性。还涵盖了利用这些衍生物调节硬脂酰辅酶A去饱和酶活性的方法，以及包含这些衍生物的药物组合物。
• Organic compounds
  申请人：Chowdhury Sultan

  公开号：US20090264444A1

  公开（公告）日：2009-10-22

  The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了调节硬脂酰辅酶A去饱和酶活性的杂环衍生物。本发明还涵盖了使用这些衍生物来调节硬脂酰辅酶A去饱和酶活性的方法和包含这些衍生物的制药组合物。
• Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
  申请人：Novartis AG

  公开号：US08063084B2

  公开（公告）日：2011-11-22

  The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了杂环衍生物，可以调节硬脂酰辅酶A去饱和酶的活性。还涵盖了使用这种衍生物来调节硬脂酰辅酶A去饱和酶的活性的方法，以及包含这种衍生物的制药组合物。
• ORGANIC COMPOUNDS
  申请人：Dales Natalie

  公开号：US20100233116A1

  公开（公告）日：2010-09-16

  The present invention provides heterocyclic derivatives hat modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了能够调节硬脂酰辅酶A脱饱和酶活性的杂环衍生物。本发明还涵盖了使用这种衍生物来调节硬脂酰辅酶A脱饱和酶活性的方法，以及包含这种衍生物的药物组合物。
• Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes
  申请人：Novartis AG

  公开号：US08049016B2

  公开（公告）日：2011-11-01

  The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了能够调节肉豆蔻酰辅酶A去饱和酶活性的杂环衍生物。本发明还涵盖使用这些衍生物调节肉豆蔻酰辅酶A去饱和酶活性的方法以及包含这些衍生物的制药组合物。